Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation

Stock Track01-05

REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.

The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.

Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155356550?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 14:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155356550","market":"nz","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation","media":"Stock Track","content":"<p>REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.</p><p>The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.</p><p>Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 7.81% in Intraday Session as Vdisituzumab Nears Breakthrough Therapy Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-05 14:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.</p><p>The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.</p><p>Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1155356550","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155356550","pubTimestamp":1767596202,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股追踪|瑞美根盘中大涨7.81%，因Vdisituzumab接近突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN (09995) surged 7.81% in the intraday session on Monday, driven by positive developments in its drug pipeline. The stock's rise follows the announcement that its drug Vdisituzumab is proposed to be included in the Breakthrough Therapy category for a new indication.The proposed use is in combination with trastuzumab and toripalimab for the first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma with high HER2 expression. This marks the fourth potential Breakthrough Therapy designation for Vdisituzumab, highlighting its clinical significance.Additionally, REMEGEN reported promising Phase I/II clinical study data for its PD-1/VEGF bispecific antibody, RC148. The data showed outstanding clinical efficacy and a manageable safety profile, further boosting investor confidence in the company's growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155356550","isCrawlerRequest":true}